EGRX Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2016 Financial Results on November 9, 2016

Eagle Pharmaceuticals, Inc. ("Eagle" or “the Company”) (Nasdaq:EGRX) announced today that the Company will release its 2016 third quarter financial results on Wednesday, November 9, 2016, before the market opens.

Scott Tarriff, President and Chief Executive Officer, and David E. Riggs, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date     Wednesday, November 9, 2016
Time 8:30 A.M. EST
Toll free (U.S.) 888-632-3384
International 785-424-1675
Webcast (live and replay)

www.eagleus.com, under the “Investor Relations” section

 

A replay of the conference call will be available for one week after the call's completion by dialing 800-374-1375 (US) or 402-220-0682 (International) and entering conference call ID EGRXQ316. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
26/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Right...

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stoc...

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results ...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quart...

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at . About Eagle Pharmaceuticals, Inc.Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarte...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at . About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meani...

 PRESS RELEASE

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Au...

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time. The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on Au...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch